• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Acumen Pharmaceuticals (ABOS)

Common Shares
Sell: $0.226|Buy: $0.23|Change: 2.08 (-90.83%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, isa subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Address




Website

https://www.acumenpharm.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Acumen Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20272027-10-26T08:00:00
Acumen Pharmaceuticals Inc Third Quarter Earnings Results for 20272027-10-26T00:00:00
Acumen Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20272027-08-12T08:00:00
Acumen Pharmaceuticals Inc Second Quarter Earnings Results for 20272027-08-12T00:00:00
Acumen Pharmaceuticals Inc Annual General Meeting for 20272027-06-03T11:00:00
Acumen Pharmaceuticals Inc First Quarter Earnings Conference Call for 20272027-05-12T08:00:00
Acumen Pharmaceuticals Inc First Quarter Earnings Results for 20272027-05-12T00:00:00
Acumen Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20262027-03-26T08:00:00
Acumen Pharmaceuticals Inc Fourth Quarter Earnings Results for 20262027-03-26T00:00:00
Acumen Pharmaceuticals Inc Annual Report for 20262027-03-26T00:00:00
19(th) Annual Clinical Trials on Alzheimer's Disease (CTAD) conference2026-11-16T00:00:00
Acumen Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20262026-10-26T08:00:00
Acumen Pharmaceuticals Inc Third Quarter Earnings Result for 20262026-10-26T00:00:00

Previous key dates

NameKey Date
Acumen Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20262026-10-26T08:00:00
Acumen Pharmaceuticals Inc Third Quarter Earnings Result for 20262026-10-26T00:00:00
Investor Day2026-09-16T10:00:00
Citi’s 2026 Biopharma Back to School Conference2026-09-10T08:40:00
Cantor Global Healthcare Conference 20262026-09-09T15:55:00
Acumen Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20262026-08-12T08:00:00
Acumen Pharmaceuticals Inc Second Quarter Earnings Result for 20262026-08-12T00:00:00
Acumen Pharmaceuticals Inc Annual General Meeting for 20262026-06-03T11:00:00
Bank of America Securities 2026 Health Care Conference2026-05-14T08:55:00
Acumen Pharmaceuticals Inc First Quarter Earnings Conference Call for 20262026-05-12T08:00:00
Acumen Pharmaceuticals Inc First Quarter Earnings Result for 20262026-05-12T00:00:00
Acumen Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20252026-03-26T08:00:00
Acumen Pharmaceuticals Inc Fourth Quarter Earnings Result for 20252026-03-26T00:00:00
Acumen Pharmaceuticals Inc Annual Report for 20252026-03-26T00:00:00
Stifel 2026 Virtual CNS2026-03-18T11:00:00
Acumen Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20252025-11-12T08:00:00
Acumen Pharmaceuticals Inc Third Quarter Earnings Result for 20252025-11-12T00:00:00
Stifel Healthcare Conference2025-11-11T16:40:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.